Clinical Trials
3 trialsNCT03823118 2023-02-23
S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung Cancer
Taizhou Hospital
Phase 2 Completed
NCT03262454 2022-04-06
Atezolizumab
National Cancer Center, Korea
Phase 2 Unknown
NCT02477813 2018-11-13
TeRes
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Terminated